Conduit Pharms Stock Price, News & Analysis

Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, has received approval from Nasdaq to transfer its common stock listing to the Nasdaq Capital Market. The transfer will be effective at market open on May 23, 2025. This approval follows the Company's confirmation of compliance with Bid Price and Equity Requirements, as previously announced on May 21, 2025.

Conduit Pharmaceuticals (NASDAQ: CDT) has successfully regained compliance with Nasdaq's listing requirements, specifically the minimum bid price requirement and stockholders' equity requirement. The clinical-stage life science company will continue to be listed and traded on the Nasdaq Stock Market.

The Nasdaq Hearing Panel has implemented a one-year Discretionary Panel Monitor starting May 15, 2025, to ensure long-term compliance with listing requirements. During this monitoring period, CDT maintains the right to request a hearing if it receives any future delisting determination letters.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) has announced a 1-for-15 reverse stock split of its common stock, effective May 19, 2025, at 5:00 pm ET. The split was approved by stockholders on May 5, 2025, and trading on a split-adjusted basis will begin on May 20, 2025, under the same ticker "CDT".

Following the split, the outstanding shares will be reduced to approximately 755,900. The par value will remain at $0.0001 per share. Proportional adjustments will be made to equity awards, convertible securities, and warrants. No fractional shares will be issued, with stockholders entitled to fractional shares receiving proportional cash payments instead.

Conduit Pharmaceuticals (NASDAQ: CDT) has secured a composition of matter patent from the Korean Intellectual Property Office (KIPO) for AZD1656, its lead asset targeting autoimmune diseases. The Glucokinase Activator's patent approval in South Korea follows recent grants in the U.S., Japan, and Australia, strengthening the company's global intellectual property position. This strategic milestone is particularly significant as South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, enhancing Conduit's presence in the valuable Asia-Pacific pharmaceutical market.

Conduit Pharmaceuticals (Nasdaq: CDT) announced significant leadership changes as founder Dr. Andrew Regan takes over as Chief Executive Officer, replacing Dr. David Tapolczay who will transition to Head of Strategy & Licensing. Dr. Tapolczay will focus on out-licensing deals for tapinarof patents.

Dr. Regan brings extensive entrepreneurial experience, including successful ventures like Hobson Plc (sold for £154 million), founding shareholder of Asos plc (reached £4.8 billion market cap), and Imperial Energy (acquired for £1.4 billion). He holds a PhD in bio-inspired algorithm development for financial market forecasting.

The company also announced that Faith Charles will step down from the Board of Directors. Under the new leadership, Conduit aims to maximize shareholder value through licensing opportunities, creating new 20-year Composition-of-Matter patents, and utilizing AI and Cybernetics in collaboration with Sarborg for drug repurposing.

Conduit Pharmaceuticals (Nasdaq: CDT) has filed two groundbreaking patents for VTAMA® (tapinarof), including a dual active cocrystal formulation that combines the drug with a complementary substance to address both therapeutic needs and side effects in inflammatory skin conditions.

The new patents come as VTAMA® approaches its 2027 exclusivity expiration. The innovation aims to enhance patient benefits by addressing symptoms like pain and itch, while extending patent protection and expanding therapeutic applications. This development is particularly significant as tapinarof enters clinical trials for cutaneous lupus and shows promise in other inflammatory and autoimmune indications.

The strategic timing aligns with the growing anti-inflammatory therapeutics market, projected to exceed $233.6 billion by 2032. The company is actively seeking partnerships to leverage this breakthrough IP while continuing to advance its broader pipeline.

Conduit Pharmaceuticals (Nasdaq: CDT) has announced a share repurchase program authorizing the buyback of up to $1,000,000 of its outstanding common stock. The company's Board of Directors initiated this program believing the current market price doesn't reflect the stock's underlying value.

The repurchase will be executed through The Benchmark Company via open market transactions or other methods compliant with SEC Rule 10b-18. The program has no fixed expiration date and can be adjusted or terminated based on market conditions, corporate liquidity, and regulatory considerations.

CEO Dr. David Tapolczay indicated the company will use existing cash reserves for potential buybacks, while maintaining focus on upcoming pipeline milestones, including preclinical data readouts and Phase II trial initiation for AZD1656.

Conduit Pharmaceuticals (Nasdaq: CDT) has expanded its partnership with Sarborg through an additional license and use agreement to enhance the analysis of its AstraZeneca-acquired assets. The collaboration focuses on applying machine learning algorithms to analyze clinical and safety data for AZD1656, AZD5658, and AZD5904.

Under the six-month non-exclusive, non-transferable license agreement, Sarborg will conduct in-depth analysis of clinical trial data to identify missed insights, drug repurposing opportunities, and data gaps. The partnership aims to evaluate historical trial data and endpoints to identify potential therapeutic benefits in specific patient subgroups, which could optimize future clinical development strategies.